Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FQWF4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $76,596
Award facts
- Contract value 100% obligated
- $76,596.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $76,596.12 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 120 capsules of XTANDI 40 MG, an oncology treatment. The delivery order, issued on December 5, 2025, with an ultimate completion date of December 8, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award was made without any identified subcontractors and represents a routine pharmaceutical supply transaction within the federal military medical system.
This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs across Department of Defense healthcare facilities worldwide. The parent IDC, designated SPE2DR and awarded on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's established performance on numerous delivery orders for diverse pharmaceutical products, including branded and generic medications, biologics, and specialty pharmaceuticals, positions the company as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQWF4?
SPE2DR26FQWF4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FQWF4 worth?
The government has obligated $76,596 on SPE2DR26FQWF4.
Is contract SPE2DR26FQWF4 an order under another contract?
Yes. SPE2DR26FQWF4 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWF4 competed?
The extent of competition for SPE2DR26FQWF4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award